Neuraura announces first patent allowed by US patent office for their core platform technology

Neuraura Biotech Inc., (Neuraura) is pleased to announce that our U.S. patent application 16/603,092 has been allowed.  This patent validates that Neuraura’s core technology, insulated microelectrodes, is unique. 

Neuraura’s core technological advantage stems from its very small, flexible electrodes that can record from and provide electrical stimulation to neural tissue.  For non-invasive stimulation, these micro-electrodes are much more effective than flat, paddle electrodes as they very slightly penetrate the outer layers of the skin, overcoming the effective barrier that the skin provides.  This technology draws on decades of research leadership in brain-chip interface from the Hotchkiss Brain Institute and advanced micro-fabrication practices from the Schulich School of Engineering.

The grant of this patent provides further recognition of the quality of the innovation being carried out by Neuraura’s team.

For more information, please email: contact@neuraura.com

About Neuraura

Neuraura’s purpose is to increase the number of quality years lived by those with under-served health conditions.  

LoOoP by Neuraura will restore women’s metabolic and reproductive health with a wearable bioelectronic device. For women with the polycystic ovarian syndrome (PCOS) symptoms and/or complications that significantly impact their quality of life, LoOoP by Neuraura will improve the way the user’s body uses blood sugar as fuel, rebalances hormones and restores regular periods.

LoOop is not available for sale at this time.

For more information, visit Neuraura’s website at https://www.neuraura.com/looop